about
Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literatureSeven fractions to deliver partial breast irradiation: the toxicity is LowAntibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancer.Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategiesAn improved sequencing-based strategy to estimate locus-specific DNA methylation.Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Immune checkpoint inhibitors and response analysis: a tough challenge. A case reportRadiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implicationsMorphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature.Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.Erratum to: Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.Carcinoma of the uterine cervix with squamous and sebaceous differentiation.In situ follicular lymphoma associated with nonlymphoid malignancies.Toxicity and cosmesis following partial breast irradiation consisting of 40 Gy in 10 daily fractions.Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.Drafting biological material transfer agreement: a ready-to-sign model for biobanks and biorepositories.Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression.Re: 18F-Fluorocholine PET/CT of Incidental Male Breast Cancer.Cost-effective organization of an institutional human cancer biobank in a clinical setting: CRO-Biobank experience toward harmonization.An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness.Ten daily fractions for partial breast irradiation. Long-term results of a prospective phase II trialCorrection to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessRole of Bruton's Tyrosine Kinase in Stage III Colorectal CancerStathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis
P50
Q33629632-6DFA4FDE-7201-432A-BECE-35D04D7BCB26Q33721910-1D732A42-3283-4B13-98D2-E09277EC4682Q33957896-7EC5BBC9-DCCB-469A-BD45-FC73B86E575CQ34996054-C102154F-4CC0-45CD-9A9D-A3C54B68A0FAQ35034978-B375DB92-9848-4480-93C3-197935989CDCQ35569457-30A70785-DDFF-4E36-B851-891623A99BD3Q35782282-15A2562C-2EFA-48C4-8762-B6E31B3E2FD5Q35789363-2A69233F-CA56-42DB-BD56-2856E1AF1831Q36080963-DFDC75ED-9F49-4607-96DB-20A2112CEFF4Q37266266-3E05FF14-C151-4A82-B284-FAF3C630ABE5Q37487689-923D4C58-D4AE-4534-A73E-6503DE294DF8Q37662085-F337A2D3-875B-45ED-8DA9-05C00738FA59Q37706763-9DDFB770-AF58-4902-B723-D4192D5D227EQ38652054-0B4DB41F-C573-4537-A3FD-D9705461BFB0Q39311503-A8A4B977-9CB8-4BF0-8023-6E080AD8D9C4Q42349878-BDDDDDEB-42C2-4EA8-80DE-A3FA14A6D00FQ42457228-138A4A77-1936-42B1-BAB9-E2D9CE813E46Q45350071-AC2A3C50-9D28-458B-A8F8-674FF36B8974Q46123164-1682A841-F86A-440B-A5F9-EF9416B4BFF0Q47348217-C694EE09-4507-4F78-ADE5-885110CD44E9Q47888140-F9D711AB-DA62-4242-8A50-1328C027224CQ49717845-DAA27356-59F6-4E20-82DA-43C70AB50A8FQ50118674-E70E3B28-6312-4876-9556-F45FD08A078CQ50580941-8B324D09-7381-4EA7-AC1D-282E293D2977Q51663878-9101CCCD-51E6-4A65-A655-C0957C1790FEQ52318631-9D4034CC-8FB2-488D-A8EB-839E35C2DB88Q91325769-B0274867-49A8-42E9-89E6-E4E5EBAB792EQ91387213-677D4CE7-AF51-4445-AF7F-B91B34704D9EQ93017736-FD0E3C58-57EA-4731-B2B6-EE85952E1372Q93381025-DC664DD7-E708-47F1-B218-6B228854F4B1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Tiziana Perin
@en
Tiziana Perin
@nl
type
label
Tiziana Perin
@en
Tiziana Perin
@nl
prefLabel
Tiziana Perin
@en
Tiziana Perin
@nl
P31
P496
0000-0002-9823-0167